LONDON (Reuters) - Researchers have high hopes for new classes of drugs that block HIV before it can enter cells, but an effective vaccine is still only a distant hope.
Pharmaceutical makers will showcase their latest advances at the International AIDS Conference in Bangkok from July 11 to 16.
Dr. Joep Lange, president of the International AIDS Society, expects a focus on experimental compounds that stop HIV from entering cells. “The inhibition of HIV entry is the field with the most promise at the moment,” Lange, a professor of internal medicine at the University of Amsterdam, said in a telephone interview.
“One of the main problems with current drugs is their long-term toxicity and particularly their metabolic side effects,” Dr. Lange said. “It is very unlikely that the entry inhibitors will give those sort of side effects.”
Switzerland’s Roche and U.S. biotech group Trimeris last year launched the first drug of this type, a fusion inhibitor. But Fuzeon is expensive, must be injected twice daily and its sales -- which totaled $24 million in the first quarter of 2004 -- have been disappointing.
Now Pfizer and Schering-Plough are racing to develop a different kind of entry inhibitor that blocks the CCR5 co-receptor for HIV, and which can be given orally.
Schering-Plough reported promising early-stage results with a compound called SCH-D in February and Pfizer is expected to report in Bangkok that its rival drug, UK-427,857, is at least as effective as existing antiretrovirals in short-term tests.
Pfizer aims to start final phase III tests later this year, according to Cathay Financial analyst Sena Lund in New York.
GlaxoSmithKline is also working on a CCR5 blocker but is believed to be further behind in development.
David Reddy, head of Roche’s HIV/AIDS business, says the war against the virus is becoming more challenging, since many of the best targets for medical intervention have already been hit.
“We’re moving into a harder era in terms of discovering new drugs, so I think some caution needs to be applied,” he said.
Vaccines are the poor relation and little concrete news is expected in Bangkok on a safe and effective product.
Trials of 30 vaccine candidates are currently underway in 19 countries -- but there is only one pivotal phase III trial and hopes for this project, involving 16,000 volunteers in Thailand, are not high following the failure of a related study last year.
“There is more effort now than there was but it is still not enough,” said Seth Berkley, president and chief executive of the non-profit International AIDS Vaccine Initiative. “An effective AIDS vaccine promises to end the epidemic. A 50% effective vaccine, given to two third of the adult population, could reduce infections up to 60%.”
To get there, Berkley wants to see 10% of global AIDS spending devoted to finding a vaccine, up from 2%-3% now.
MeSH Headings:Drugs, Investigational: Anti-HIV AgentsCopyright © 2002 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.
